How Should Multi-Compound Peptide Trackers Model Overlapping Dosing Windows When Users Run GLP-1, Amylin, and Dual-Agonist Stacks Together in 2026?

Multi-compound peptide trackers running GLP-1, amylin, and dual-agonist stacks in 2026 must model each compound's individual half-life and tmax as independent exposure curves, then calculate the overlap zone where two or more curves exceed 50% of peak concentration simultaneously. Without this per-compound PK layer, a tracker cannot distinguish a true dosing gap from residual long-half-life exposure.

Why Do Flat Dosing Schedules Fail for GLP-1 and Amylin Combinations?

Flat schedules assign a dose event to a calendar slot but carry no exposure memory between events. For compounds with half-lives measured in days — semaglutide at approximately 165–168 hours and cagrilintide at 159–195 hours — a flat schedule cannot represent the fact that meaningful plasma concentrations persist for four to five dosing intervals after the last injection.

The Enebo et al. Phase 1b co-administration trial (Lancet, 2021) confirmed that when semaglutide 2.4 mg and cagrilintide are dosed together weekly, both compounds reach steady state only after four to five weeks of consecutive dosing. A flat-schedule tracker logging "dose taken" on day 7 has no mechanism to represent that the user is still in a rising accumulation phase, not a stable trough-to-peak cycle.

This matters for overlap modeling because the pharmacodynamic interaction between GLP-1R agonism and amylin receptor agonism is additive on satiety circuits. If a tracker cannot flag that both compounds are simultaneously above 80% of steady-state concentration, it cannot alert the user to the period of maximal combined appetite suppression — the window most relevant for caloric intake planning and nausea risk assessment.

What PK Parameters Must Each Compound Class Contribute to the Tracker Model?

Each compound class requires four parameters to build a usable exposure curve: elimination half-life, time to peak concentration, route-specific bioavailability, and the number of doses required to reach steady state. For weekly subcutaneous incretin-class compounds, steady state is typically reached at four to five half-lives, spanning three to five weeks of consecutive weekly dosing.

For GLP-1 receptor agonists, semaglutide has an elimination half-life of approximately 165–168 hours and reaches peak concentration 12–24 hours after subcutaneous injection (FDA NDA 213051 Clinical Pharmacology Review). Tirzepatide has a shorter half-life of approximately 120 hours with a similar tmax of roughly 24 hours (Schneck et al., CPT:PSP, 2024; FDA NDA 215866).

For amylin receptor agonists, cagrilintide carries an elimination half-life of approximately 159–195 hours and reaches peak concentration 24–72 hours post-injection (Enebo et al., Lancet, 2021). For triple agonists, retatrutide has a half-life of approximately 6 days and a tmax of roughly 24–48 hours (Jastreboff et al., NEJM, 2023).

For the unimolecular GLP-1/amylin dual agonist amycretin, once-weekly subcutaneous dosing at up to 60 mg produced 24.3% weight loss at 36 weeks with PK consistent with weekly administration (Dahl et al., Lancet, 2025). A tracker modeling a retatrutide-plus-cagrilintide stack must represent two overlapping curves with similar half-lives but mechanistically distinct receptor targets — a near-congruence that flat-schedule tools cannot represent.

How Should Trackers Calculate the Overlap Zone Between Two Long-Half-Life Compounds?

The overlap zone is the time interval during which both compounds simultaneously exceed a defined exposure threshold — typically 50% of steady-state Cmax. Trackers should compute this by modeling each compound as a one-compartment accumulation curve using the standard multiple-dose equation, then flagging the intersection window on the user's calendar.

For a semaglutide-plus-cagrilintide stack dosed on the same day each week, both compounds have half-lives of approximately 7 days. This means each compound's trough concentration at the end of a dosing interval is approximately 50% of its steady-state Cmax. The overlap zone is therefore continuous — both compounds remain above 50% Cmax throughout the entire dosing interval once steady state is reached, typically by week four or five.

The tracker implication is that there is no "gap" to schedule around for this particular combination. The modeling task shifts from identifying overlap windows to identifying the accumulation ramp — the first three to four weeks during which combined exposure is still rising. Trackers that display a static "week 1 = dose 1" view without a rising-curve indicator will misrepresent the user's actual exposure state during this critical titration phase.

For a tirzepatide-plus-cagrilintide stack, the shorter tirzepatide half-life (~5 days versus ~7 days for cagrilintide) creates a modest asymmetry: tirzepatide trough concentrations fall slightly lower relative to Cmax at the end of each weekly interval. A tracker should represent this as two curves with slightly different trough depths, not as a single combined curve.

How Does a Single-Molecule Dual Agonist Like Amycretin Change the Tracker Architecture?

A single-molecule dual agonist such as amycretin collapses two receptor-activation curves into one PK curve, eliminating the inter-compound timing variable entirely. The tracker needs only one exposure curve, one tmax, and one half-life estimate. This simplifies the overlap model but introduces a fixed GLP-1R:amylin receptor activity ratio that cannot be adjusted independently.

Amycretin's Phase 1b/2a subcutaneous trial (Dahl et al., Lancet, 2025) demonstrated once-weekly dosing with a PK profile consistent with weekly administration, producing 24.3% mean weight loss at 36 weeks. Because both receptor activities are encoded in a single molecule, the tracker cannot model a scenario where the user adjusts the amylin component independently — a constraint that two-compound stacks do not have.

For protocol designers comparing amycretin against a CagriSema (cagrilintide + semaglutide) stack, the tracker architecture must reflect this distinction. CagriSema requires two independent exposure curves with separate dose-event logging; amycretin requires one. A tracker that treats both as equivalent "two-receptor stacks" will produce incorrect overlap calculations for the two-compound version and will incorrectly suggest dose-ratio flexibility for the single-molecule version.

What Secondary Interaction Layer Do GLP-1 Agents Add via Gastric Emptying Delay?

GLP-1 receptor agonists slow gastric emptying, altering the absorption kinetics of any orally co-administered compound. This creates a pharmacokinetic interaction layer — not a receptor-level collision — where the GLP-1 agent delays the oral compound's tmax and reduces its peak concentration. Trackers modeling oral companion compounds alongside subcutaneous GLP-1 stacks must account for this absorption-delay vector separately.

The 2024 comprehensive review by Calvarysky (PMC11018670) and the 2025 Hooper et al. analysis (Pharmacotherapy) both confirm that GLP-1RA-induced gastric motility delays are clinically relevant for narrow-therapeutic-index oral drugs. For peptide tracker users also logging oral metformin, levothyroxine, or cyclosporine alongside a GLP-1 stack, the overlap model must flag the absorption-delay risk as a distinct interaction node from receptor-level overlap.

This is architecturally distinct from the half-life overlap problem. The gastric emptying interaction is dose-dependent and partially reversible — most pronounced at peak GLP-1 plasma concentrations within 12–24 hours of injection and attenuating toward the trough. A tracker can model this as a time-varying absorption modifier: high-risk window within 24 hours post-injection, moderate risk at 24–72 hours, low risk at trough.

What Does a Correct Stack Blueprint Look Like for a Three-Compound GLP-1 / Amylin / Dual-Agonist Tracker?

A correct tracker blueprint for a three-compound incretin stack separates each compound into its own PK lane, calculates independent accumulation curves, then renders a combined exposure heatmap showing the overlap zone by week. The blueprint must include a steady-state flag at week four to five, a trough-depth indicator per compound, and a gastric-emptying alert for any oral co-medications.

What Are the Most Common Modeling Errors in Current Peptide Tracker Implementations?

The most common modeling errors in current peptide tracker implementations are: treating all compounds as having the same exposure duration regardless of half-life, displaying a "next dose due" countdown without a residual-exposure indicator, and failing to distinguish between a two-compound stack and a single-molecule dual agonist. Each error produces a different category of incorrect overlap output.

Treating all compounds as equivalent in duration is the most consequential error. A tracker that models semaglutide (half-life approximately 7 days) with the same exposure decay as a short-acting peptide like AOD-9604 (half-life approximately 4 minutes) will show a false gap between doses where no pharmacological gap exists. For incretin stacks specifically, this error leads users to believe they have a "reset window" between weekly injections — a window that does not exist at steady state.

The second common error is conflating the dosing event with the exposure event. The dose event is a point in time; the exposure event is a curve. Trackers that log only the dose event cannot represent the accumulation ramp, the steady-state plateau, or the trough depth — three features of the exposure curve that determine whether two compounds are truly overlapping at any given moment.

The third error — failing to distinguish single-molecule from two-compound dual agonists — becomes increasingly consequential as amycretin and similar unimolecular agents enter wider use. A tracker that allows independent dose adjustment of "GLP-1 component" and "amylin component" for an amycretin user is modeling a degree of freedom that does not exist in the molecule. Does Orforglipron Meaningfully Change Fasting Tolerance, Meal Timing, or Protein Intake Patterns Compared With Injectable Incretins in 2026? Does Oral GLP-1 Receptor Agonism Now Have Clinical Proof Beyond Injectable Peptides — How Do 2026 Oral Obesity Trials Compare with Semaglutide and Tirzepatide on Weight Loss and Tolerability? What Does 2026 Research Show About Semaglutide Therapy Trends and Strategies to Improve Its Bioavailability?